Reading time: mins
Sydney Heart Team principal, Professor Michael Vallely, describes how to establish a TAVI program in the attached paper.
Professor Vallely highlights some of the key philosophies and approaches of our program, including:
Sydney Heart Team is evaluating a new device designed to treat a common condition that can lead to heart failure. Tricuspid regurgitation occurs when the tricuspid valve fails to close properly and blood flows backwards into the atrium, forcing the right side of the heart to work harder and causing extreme fatigue, shortness of breath, […]
A new minimally invasive treatment is offering hope to Australians living with severe angina that has not improved despite medications, stents or bypass surgery. Angina—chest discomfort caused by reduced blood flow to the heart—is one of the most common symptoms of coronary heart disease. For most people, medications or procedures such as stents or bypass […]
Transcatheter mitral valve repair (TMVr) with the MitraClip device is an increasingly important part of the clinical armamentarium for treatment of mitral regurgitation (MR). TMVr provides significant quality of life and prognostic benefits in patients with functional MR who remain symptomatic despite optimal medical therapy. Furthermore, TMVr is an important treatment option in patients with […]
